Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Pediatrics · Glycogen Storage Disease Type Ia

Watching for the Long Term: Monitoring and Complications

At a Glance

Long-term management of Glycogen Storage Disease Type Ia (GSD Ia) requires strict metabolic control and routine screening to prevent severe complications. Regular surveillance using ultrasounds, DCP tumor markers, and urine tests is essential to catch silent liver adenomas and kidney damage early.

While the day-to-day focus of Glycogen Storage Disease Type Ia (GSD Ia) is on blood sugar, the goal of long-term management is to protect the liver and kidneys from the silent effects of “metabolic reprogramming” [1][2]. Even when a child seems healthy, consistent monitoring is essential to catch and manage complications early.

Hepatic (Liver) Risks and Surveillance

The liver in GSD Ia is under constant stress from stored glycogen and fat. Over time, this can lead to the development of hepatocellular adenomas (HCA), which are benign (non-cancerous) liver tumors [3][4].

  • Tumor Risk: In some cases, these adenomas can undergo “malignant transformation,” meaning they turn into hepatocellular carcinoma (HCC), a form of liver cancer [3][5].
  • The Monitoring Challenge: In many other liver diseases, a marker called alpha-fetoprotein (AFP) is used to find cancer. However, in GSD Ia, AFP levels are often normal even when a tumor is present [3]. Therefore, doctors use a different marker called des-gamma-carboxy prothrombin (DCP) alongside frequent imaging [3][6].

Renal (Kidney) Risks

High levels of uric acid, triglycerides, and lactate can gradually damage the small filters in the kidneys [1][7].

  • Silent Damage: Kidney issues often begin without any symptoms. The first sign is often microalbuminuria (small amounts of protein in the urine) or proteinuria [1].
  • Prevention: Maintaining strict metabolic control can not only slow this damage but sometimes even reverse early protein leakage [1].

Gout and Uric Acid

When the liver is “backed up” with sugar, it produces excess uric acid [8]. If uric acid levels stay high for years, crystals can form in the joints, leading to gout [9].

  • Early Onset: While most people think of gout as an adult disease, children with GSD Ia can develop “young-onset gout” as early as their second decade of life (the teenage years) [9][10].

Your Surveillance Checklist

Regular check-ups are the best defense against long-term complications. Use this checklist to stay on track with your medical team:

Category Test/Tool Frequency (Typical) Goal in GSD Ia
Metabolic Stability Blood Glucose Daily via fingerstick or CGM >70 mg/dL (3.9 mmol/L) [11][12]
Blood Lactate Regular Clinic <2.2 mmol/L [13]
Uric Acid Regular Clinic Low-to-normal range [9]
Triglycerides Regular Clinic <6.0 mmol/L (preferably lower) [13]
Liver Health Ultrasound/MRI Every 6–12 months Monitor size and check for adenomas [3]
Tumor Marker (DCP) Every 6–12 months Screen for HCC risk [3]
Kidney Health Urine Protein At least annually Detect microalbuminuria early [1]
Ultrasound Every 12 months Monitor for stones or structural changes [1]

Consistent dietary adherence remains the single most effective way to keep these markers in their target ranges and protect your child’s long-term health [1][14].

Return to the Understanding Your Child’s GSD Ia Diagnosis.

Common questions in this guide

Why is the DCP test used instead of AFP for tumor screening in GSD Ia?
In many liver diseases, alpha-fetoprotein is used to detect cancer, but in GSD Ia, these levels are often normal even if a tumor is present. Doctors use des-gamma-carboxy prothrombin (DCP) alongside regular imaging because it is a more reliable marker for liver tumors in this specific condition.
What are the early signs of kidney involvement in GSD Ia?
Kidney damage in GSD Ia often begins silently without noticeable symptoms. The first medical sign is typically microalbuminuria, which is the presence of small amounts of protein in the urine detected during regular lab tests.
Can children with GSD Ia get gout?
Yes, children with GSD Ia can develop young-onset gout, sometimes as early as their teenage years. This happens when the liver is stressed and produces excess uric acid, which can build up and form crystals in the joints.
How often should my child have a liver ultrasound for GSD Ia?
Current surveillance guidelines recommend a liver ultrasound or MRI every 6 to 12 months. This routine imaging helps doctors monitor liver size and check for the development of benign tumors called hepatocellular adenomas.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.At what size or number of liver adenomas do you recommend considering a surgical intervention or a change in management?
  2. 2.What is the target uric acid level for my child, and when would we consider starting medication like allopurinol?
  3. 3.How often should we be screening for microalbuminuria to check for early signs of kidney involvement?
  4. 4.Why is des-gamma-carboxy prothrombin (DCP) used for tumor screening in GSD Ia instead of the standard alpha-fetoprotein (AFP) test?
  5. 5.Can you help us understand the results of our child's latest liver ultrasound and if there have been any changes since the last one?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

    Okechuku GO, Shoemaker LR, Dambska M, et al.

    Journal of inherited metabolic disease 2017; (40(5)):703-708 doi:10.1007/s10545-017-0054-2.

    PMID: 28612263
  2. 2

    Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control.

    Dambska M, Labrador EB, Kuo CL, Weinstein DA

    Pediatric diabetes 2017; (18(5)):327-331 doi:10.1111/pedi.12540.

    PMID: 28568353
  3. 3

    Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia.

    Arnson B, Kang HR, Brooks ED, et al.

    Molecular therapy. Methods & clinical development 2023; (29()):108-119 doi:10.1016/j.omtm.2023.03.001.

    PMID: 37021039
  4. 4

    Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.

    Kang HR, Gjorgjieva M, Smith SN, et al.

    Molecular therapy. Methods & clinical development 2019; (15()):383-391 doi:10.1016/j.omtm.2019.10.016.

    PMID: 31890731
  5. 5

    A case study of glycogen storage disease type Ia presenting with multiple hepatocellular adenomas: an analysis by gadolinium ethoxybenzyl-diethylenetriamine-pentaacetic acid magnetic resonance imaging.

    Li X, Jing H, Cheng L, et al.

    Quantitative imaging in medicine and surgery 2021; (11(6)):2785-2791 doi:10.21037/qims-20-746.

    PMID: 34079743
  6. 6

    Proteomics profiling of serum and liver in GSD Ia and Ib patients: insights into complication mechanisms and circulation biomarkers.

    Xiao R, Gross-Valle C, Gerding A, et al.

    Journal of translational medicine 2026; (24(1)).

    PMID: 41721410
  7. 7

    Inhibition of Wnt/β-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia.

    Lee C, Pratap K, Zhang L, et al.

    Biochimica et biophysica acta. Molecular basis of disease 2024; (1870(1)):166874 doi:10.1016/j.bbadis.2023.166874.

    PMID: 37666439
  8. 8

    Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.

    Cho JH, Kim GY, Mansfield BC, Chou JY

    Biochemical and biophysical research communications 2018; (498(4)):925-931 doi:10.1016/j.bbrc.2018.03.083.

    PMID: 29545180
  9. 9

    Clinical features of gout in adult patients with type Ia glycogen storage disease: a single-centre retrospective study and a review of literature.

    Xu N, Han X, Zhang Y, et al.

    Arthritis research & therapy 2022; (24(1)):58 doi:10.1186/s13075-021-02706-5.

    PMID: 35219330
  10. 10

    Tophaceous gout in a female premenopausal patient with an unexpected diagnosis of glycogen storage disease type Ia: a case report and literature review.

    Zhang B, Zeng X

    Clinical rheumatology 2016; (35(11)):2851-2856 doi:10.1007/s10067-016-3290-1.

    PMID: 27139513
  11. 11

    A triple-blinded crossover study to evaluate the short-term safety of sweet manioc starch for the treatment of glycogen storage disease type Ia.

    Monteiro VCL, de Oliveira BM, Dos Santos BB, et al.

    Orphanet journal of rare diseases 2021; (16(1)):254 doi:10.1186/s13023-021-01877-3.

    PMID: 34082801
  12. 12

    Type la glycogen storage disease complicated with diabetes mellitus: the role of flash continuous glucose monitoring.

    Marcalo J, Oliveira A, Nunes PA, do Vale S

    BMJ case reports 2021; (14(3)) doi:10.1136/bcr-2020-240489.

    PMID: 33766968
  13. 13

    Severe perioperative lactic acidosis in a pediatric patient with glycogen storage disease type Ia: a case report.

    Takahashi T, Oue K, Imado E, et al.

    JA clinical reports 2023; (9(1)):91 doi:10.1186/s40981-023-00683-z.

    PMID: 38114842
  14. 14

    Case Report: Glycogen Storage Disease Type Ia in a Chinese Child Treated With Growth Hormone.

    Wu S, Guo S, Fu L, et al.

    Frontiers in pediatrics 2022; (10()):921323 doi:10.3389/fped.2022.921323.

    PMID: 35783312

This page provides educational information on long-term monitoring for GSD Ia. It does not replace professional medical advice. Always consult your metabolic specialist for your child's specific surveillance plan.

Get notified when new evidence is published on Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.